Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 11/20 | 0.49 |
| ▸ | INSR | P06213 | 10/20 | 0.49 |
| ▸ | IGF1R | P08069 | 10/20 | 0.49 |
| ▸ | TTK | P33981 | 2/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.45 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | STK10 | O94804 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | CD74 | P04233 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044690 | 0.79 | EGFR (0.59) | EGFRALKINSRIGF1RPTK2 | |
| SCHEMBL935724 | 0.74 | CDC7 (0.60) | EGFRINSRLRRK2CHEK1CHEK2 | |
| SCHEMBL4767413 | 0.74 | TTK (0.66) | ALKINSRIGF1RTTKPTK2 | |
| SCHEMBL935104 | 0.72 | CDC7 (0.64) | EGFRINSRLRRK2CHEK1CHEK2 | |
| SCHEMBL10156861 | 0.71 | ALK (0.73) | ALKINSRIGF1RTTKPTK2 | |
| SCHEMBL18194356 | 0.71 | ALK (0.61) | EGFRALKINSRIGF1RTTK | |
| SCHEMBL3131543 | 0.71 | TTK (0.64) | ALKINSRIGF1RTTKPTK2 | |
| SCHEMBL26087590 | 0.70 | ALK (0.73) | EGFRALKINSRIGF1RTTK | |
| SCHEMBL1491729 | 0.70 | ALK (0.77) | EGFRALKINSRIGF1RTTK | |
| SCHEMBL4767418 | 0.70 | TTK (0.60) | ALKINSRIGF1RTTKPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454262-B1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LAB (US) | 2014-05-14 | — | — | EP | claimed |
| EP-2454262-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | claimed |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | claimed |
| WO-2011008830-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | claimed |
| EP-2454262-B1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LAB (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8383624-B2 | Pyrrolopyrazine inhibitors of kinases | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2454262-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011008830-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | CDC7, CDK7, CDK17 | EGFR 1450/4885ALK 1579/4885INSR 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.